Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1912 plus immunochemotherapy in B-cell non-Hodgkin lymphoma (phase Ib/II)
CTR20233679Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SHR-A1912 in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Hengrui Therapeutics. Primary endpoints: Recommended phase II dose (RP2D) of SHR-A1912 plus immunochemotherapy, Incidence and severity of adverse events and laboratory abnormalities and 1 more. Started Nov 2023; status: active.
02
Drugs
SHR-A1912
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on CTR20233679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233679.